Boston Scientific Corporation
BSX-PA
New York Stock Exchange122.18
USD
+2.83
- -
CIK
0000885725
ISIN
US1011372067
CUSIP
101137206
Return %
Stock
S&P500
1Y
20.45
26.84
3Y
16.71
77.03
5Y
17.48
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael F. Mahoney
- Full Time Employees
- 45,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 22, 2020
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation develops, manufactures, and markets a broad range of medical devices used in various interventional medical specialties worldwide. Its core product portfolio includes cardiovascular devices such as drug-eluting stents including the platinum chromium-based TAXUS Element and PROMUS Element stent systems; electrophysiology and rhythm management devices including pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and subcutaneous ICDs; endoscopy products; urology and pelvic health devices; neuromodulation technologies for chronic pain management including spinal cord stimulators; peripheral interventions; and interventional oncology devices. The company serves healthcare professionals and institutions across more than 100 countries and operates commercial representation in 127 countries. Founded in 1979, Boston Scientific is headquartered in Marlborough, Massachusetts. Recent major changes include multiple acquisitions made during 2024 and 2025 to expand its product capabilities and market reach. Notable acquisitions include Axonics, Inc. in late 2024 for $3.7 billion to grow its urology and pelvic health business; Nalu Medical, Inc. in 2025 to enhance neuromodulation offerings for chronic pain; SoniVie Ltd. to add ultrasound-based renal denervation therapy for hypertension; and Anrei Medical to bolster its endoscopy portfolio. Additionally, it acquired Cortex and Bolt Medical, the latter known for the Bolt IVL system, a laser-based platform for treating artery disease. Boston Scientific also acquired Elutia's BioEnvelope business targeting post-operative complications and recently announced the acquisition of California medical equipment businesses. The company continues to launch innovative products including the anticipated FDA approval of the Agent drug-coated balloon for coronary artery disease treatment and the Farapulse pulsed-field ablation system for atrial fibrillation, alongside expanding spinal cord stimulation indications to address painful diabetic peripheral neuropathy. Boston Scientific invests heavily in research and development, with $1.6 billion spent in 2024, yielding nearly 100 new product launches that year. It employs over 53,000 people globally and treats more than 44 million patients annually. Its strategic focus remains on interventional cardiology, electrophysiology, endoscopy, urology and pelvic health, neuromodulation, peripheral interventions, and oncology segments, leveraging acquisitions, clinical advancements, and innovative device technologies to sustain growth and market leadership in medical technology. This comprehensive product development and acquisition strategy marks Boston Scientific as a leading global medical device company with broad geographic and clinical reach, addressing complex and chronic medical conditions through advanced interventional solutions.